Excellamol
- Biotech or pharma, therapeutic R&D
Excellamol develops polypeptide-drug conjugates for patients with rare pediatric diffuse midline glioma and adult glioblastoma. To date, Excellamol has invested a total of $1 million, resulting in two FDA Orphan Drug Designations for high-grade gliomas and a candidate for Rare Pediatric Disease Designation, and is now launching a Series A financing round to support Phase 0/1 clinical trials. If your company is exploring in-licensing opportunities, investment, strategic partnerships, or M&A, we would welcome the opportunity to connect and discuss potential collaboration.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}